J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson beat Q2 estimates with sales of $25.31B (+6.6% YoY) vs ~$25.05B expected and adjusted EPS of $2.90 vs $2.85. Growth from Tremfya (+72.5% to $2.0B) and Darzalex ($4.2B) offset erosion from older products, while Abiomed pump sales fell 2% YoY amid new UK study scrutiny. J&J raised FY sales guidance to ~$101.1B (midpoint) from $100.8B and lifted adjusted EPS to $11.68 from $11.55, supporting a bullish read-through as the company expects Abiomed to return to growth.

Analysis

JNJ is starting to look less like a slow-growth defensive and more like a self-funded compounder: the important mechanism is that stronger immunology traction lowers the market’s estimate of the Stelara hole, which should support a modest multiple rerating over the next 1-3 months. The immediate beneficiary is JNJ equity, but the second-order effect is broader sector rotation toward diversified pharma that can still grow after a patent cliff.

The medtech weakness is the swing factor. If the Abiomed pause is just study-headline deferral, the drawdown should reverse as data accumulates; if not, the market will keep assigning a conglomerate discount to the group and may treat device exposure as an ongoing earnings drag. That matters for device peers and suppliers too: persistent Impella scrutiny would help competing structural-heart platforms at MDT/BSX, while a clean rebound would reassert JNJ’s diversification premium.

Contrarian view: the beat is good, but the EPS raise is still mostly mix-driven rather than a step-change in durable earnings power. Consensus may be overconfident that Tremfya can fully offset patent erosion without any air pockets, so the upside is likely better on dips than on strength unless the next two quarters confirm sustained high-20s growth and device stabilization. Falsifiers are a sequential slowdown in Tremfya or another quarter of Abiomed deterioration.

Key Decisions for Investors

• Buy JNJ on any 1-2% post-earnings pullback over the next 1-2 weeks; target a 5-8% move over 1-3 months as estimates reset higher, with a stop if next-quarter pharma growth decelerates meaningfully or FY EPS slips back below the raised guide.
• Pair trade: long JNJ / short ABBV for a 1-3 month relative-value position if you believe JNJ’s immunology replacement path is underappreciated and ABBV’s IL-23/Rinvoq expectations are already richer; cover if ABBV re-accelerates in its next guidance print.
• Set a watch alert on Abiomed/Impella momentum into the first-half-next-year data release; if sales stay negative or the study overhang broadens, fade any JNJ rally and consider hedging with IHI rather than buying medtech beta outright.